February 10, 2023
Takeda Pharmaceutical said on February 9 that it has completed the acquisition of an investigational immune therapy program NDI-034858 from Nimbus Therapeutics through the purchase of the US biotech’s relevant subsidiary. NDI-034858 is an oral, selective allosteric tyrosine kinase 2...read more